Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,637.3 million
Deal Type : Acquisition
Mankind Pharma Completes Landmark Acquisition of BSV
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (carboprost tromethamine), which is indicated for the treatment of post partum haemorrhage.
Product Name : Endoprost
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,637.3 million
Deal Type : Acquisition
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.
Product Name : Endoprost
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 26, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
Lead Product(s) : Isoxsuprine Hydrochloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Jagdale Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Bharat Serums and Vaccines Acquires Key Women Health Brand Tidilan from Jagdale Industries
Details : Tidilan is currently available in tablet and injectable dosage forms. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, Hucog 5000 HP, AntiD among others.
Product Name : Tidilan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 04, 2022
Lead Product(s) : Isoxsuprine Hydrochloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Jagdale Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Recombinant-Human Follicle Stimulating Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recombinant Follicle-stimulating Hormone in Treatment for Infertility
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 04, 2022
Lead Product(s) : Recombinant-Human Follicle Stimulating Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 04, 2021
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicord
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 08, 2021
Lead Product(s) : Epicord
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bharat Serums to assess sepsis drug Ulinastatin for Covid-19
Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable